)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Elicera Therapeutics
Elicera Therapeutics (ELIC) investor relations material
Elicera Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Operating loss for Q2 2026 was SEK -6.3 million, with a net loss of SEK -6.3 million and EPS of SEK -0.12, reflecting increased R&D and operational activities compared to Q2 2025.
For H1 2026, operating loss reached SEK -11.4 million, net loss SEK -11.3 million, and EPS SEK -0.22, showing a slight increase in losses year-over-year.
Strong clinical progress in the CARMA study, with 91% tumor response rate and 6 of 8 patients achieving complete metabolic response.
Successful rights issue raised SEK 54.6 million, strengthening financial position and supporting ongoing clinical programs.
Leadership transitions include a new CEO and Chair, with continuity ensured in scientific and operational management.
Financial highlights
Q2 2026 operating loss: SEK -6.3 million (vs. SEK -2.9 million in Q2 2025).
H1 2026 operating loss: SEK -11.4 million (vs. SEK -11.0 million in H1 2025).
Cash flow from operations in H1 2026: SEK -10.9 million (vs. SEK -6.7 million in H1 2025).
EPS for H1 2026: SEK -0.22 (vs. SEK -0.25 in H1 2025).
Rights issue provided SEK 54.6 million before costs.
Outlook and guidance
Capital raised will fund completion of CARMA study and accelerate ELC-401 clinical preparations.
Preparations for ELC-401 clinical trial are on track, with regulatory guidance received and process development underway.
Ongoing recruitment for new CEO and continued focus on advancing pipeline.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elicera Therapeutics
- Losses widened, cash burn increased, and new financing and collaborations advanced the pipeline.ELIC
Q2 2024 - Improved Q1 results and robust clinical advances, with strong CARMA study outcomes.ELICQ1 2026
- Promising clinical results and stable cash position despite increased losses in 2025.ELICQ4 2025
- Returned to operating profit in Q3 2025 with strong clinical and financial progress.ELICQ3 2025
- Improved financials, strong CARMA study results, and funding secured through mid-2027.ELICQ2 2025
- Q3 loss narrowed, clinical milestones reached, and rights issue strengthened liquidity.ELICQ3 2024
- Q1 2025 saw a wider loss but strong financing and promising clinical progress for Elicera.ELICQ1 2025
- Annual loss narrows as clinical milestones and new financing strengthen Elicera's outlook.ELICQ4 2024
Next Elicera Therapeutics earnings date
Q3 202627 Nov, 2026
Elicera Therapeutics
Next Elicera Therapeutics earnings date
Q3 202627 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage